The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Perhaps recruitment wasn't done willy-nilly and the milder cases mentioned still had significant symptoms. Obviously home treatment will be for milder cases, otherwise they would be in hospital, but milder doesn't necessarily = mild.
Good find, next few weeks we should get the results and then progress into P3 with a 1000 patients. Patience then required!
Top post sizz, keep the faith!
I have held these shares for a while now and it's fair to say my life savings are in the hands of Synairgen and Richard Marsden.
I have watched this board daily for some 12 months now. I have seen far more lows than highs. Some lows have been frightening, really low. That said I still believe we are firmly on course to break £5 per share, all the news has been positive. So I ignore the noise and remain confident we will see better days. This share is not for the faint hearted that's for sure but I am standing firm for the day we investors are rewarded for staying the course and supporting SNG and this breakthrough Covid 19 treatment!
1 year from now the new penicillin ? It’s potentially that big .COVID is here to stay ,
Out of the box
SNG001 is given to lower and higher risk participants, so not just lower risk.
Id think most people under 30 aren’t going to join a trial because they feel they’re invincible unless there’s money involved in recruitment.
It’s far more likely we have older patients in our group who take this virus more seriously
So long as 2 or 3 on placebo have been hospitalised compared to 0 SNG, you would hope the combined data would be sufficient to progress to 3, when hopefully we can target breathlessness and have a greater impact.
I'm sure they are not looking to remove a drug that works because dosing has been at the wrong time, when we now know when it is most effective.
*'..the injected or infused agents are being reserved for the more seriously ill patients.'
unfortunately Doc, we already know we are not getting the more seriously ill patients on our P2 ACTIV-2, the panellist told us that in the interview.
'Interferon-Beta is being used on mild outpatient cases, the seriously ill patients are being reserved for the injected or infused agents'
hTTps://www.facebook.com/kuhospital/videos/1116924078826762/
Apologies: Tonlin
Tonkin
You’ve obviously overlooked the worldwide Phase3 hospital trials that we as investors have financed.
This is where the big returns will come from in treating this current pandemic and pandemics of the future with stockpiling, check out the RNS business case.
ACTIV2 if successful is a nice to have bolt on but not an all or nothing.
Here's what the protocol says on trial size for ACTIV-2 .
Approximately 110 participants per investigational agent (and 110 on placebo) in the phase II evaluation. For infused agents, approximately 421 participants per investigational agent (and 421 on placebo), in the phase III evaluation (including those enrolled in phase II). The sample size for Phase III for non-infused agents will be included in a subsequent version of the protocol.
Tonlin - you mean ACTIV-2 phase III not ACTIV-3.
Where does it put us if we do not progress to Activ3? The credibility of RM, SSH and the company would be in tatters. Thus far there appears such confidence from interviews with RM, statements in RNS's that it seems almost inconceivable that we won't progress. I know nothing is confirmed until it is (obviously) but lack of progress would scupper our involvement in COVID and we would be back to developing COPD treatments (as valuable as that is). Doesn't bear thinking about. So I won't.
Jim.... perhaps he meant 110 dosed with the drug (together with 110 on placebo). Just a guess.
Thanks Sandy - good find.
One can go straight to that part of the discussion with Dr. Mario Castro around 35 mins in.
It also might suggest that they’re going to use 110 US patients + the existing UK home trial data to make the decision on progression, as it was supposed to be 220 patients on Activ-2 iirc.
Tricky - progression is not a given sadly. Plus potentially less at risk patient population on the trial. Still quite a bit of risk here.
Great find Sandy. So the scientists heading up Activ2 are saying recruitment will be completed within 2 weeks and then they will roll straight into phase 3 for Activ2. They are excited about the potential for home use- saving on health costs and reducing pressure on hospitals. The enrolment target is 120 people all of whom will have mild covid. So a much better sample size than the early report for home trials. That's something to look forward to. We should have results for phase 3 Activ2 before the hospital trials then.
It helps the immune system ramp up a bit quicker